Company news: HBA and Cardinal Health; Bristol-Myers Squibb; Spyglass; Cochrane
Efficacy, not safety has come between Bristol-Myers Squibb and its experimental Alzheimer's treatment, avagacestat. The company has decided to abandon the Phase II drug, reported Bloomberg Tuesday. The drug targeted plaques, and Bloomberg noted that the company remains committed to tackling beta amyloids as a solution pathway.
Nurses aren't big on iPads, or tablets as a whole, according to a survey of more than 100 acute care nurses by the consulting group Spyglass, reported MobiHealth News. The study found that the reason behind the nurses' disdain for tablets included durability issues, infection control and limited data entry. As a kicker, MobiHealth added that a quarter of the polled nurses were also unhappy with their facilities' wireless networks. Despite the connectivity issues, Spyglass found that 45% of clinicians use mobiles to collect bedside data, up from 30% last year. They also found that they were also increasingly using camera phones to capture patient data.
Texting isn't just good for helping new moms. It's also good for helping smokers become ex-smokers, according to studies published by the Cochrane Collaboration, reported NPR. Like Text4Baby, the texting programs polled contacted subscribers with tips. In this case, the program set a series of motivational advice, tips and video links throughout the day. The program also included customized information, with the authors noting that subscribers could text “Crave” and receive strategies to resist the urge to smoke, such as taking a walk or grabbing a snack. Researchers estimated the programs “increased the chance of quitting in at least six months – from four to five percent in control groups, to between 6 and 10 percent in the texting groups.”